As of 2024-12-14, the EV/EBITDA ratio of Egetis Therapeutics AB (publ) (EGTX.ST) is -8.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. EGTX.ST's latest enterprise value is 2,314.02 mil SEK. EGTX.ST's TTM EBITDA according to its financial statements is -258.90 mil SEK. Dividing these 2 quantities gives us the above EGTX.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 22.3x - 26.2x | 26.0x |
| Forward P/E multiples | 20.8x - 25.4x | 23.4x |
| Fair Price | (15.87) - (18.11) | (17.57) |
| Upside | -338.0% - -371.5% | -363.5% |
| Date | EV/EBITDA |
| 2024-12-09 | -8.38 |
| 2024-12-06 | -8.34 |
| 2024-12-05 | -7.62 |
| 2024-12-04 | -7.54 |
| 2024-12-03 | -7.13 |
| 2024-12-02 | -7.48 |
| 2024-11-29 | -7.47 |
| 2024-11-28 | -7.18 |
| 2024-11-27 | -7.19 |
| 2024-11-26 | -7.45 |
| 2024-11-25 | -7.51 |
| 2024-11-22 | -7.09 |
| 2024-11-21 | -7.18 |
| 2024-11-20 | -7.22 |
| 2024-11-19 | -7.09 |
| 2024-11-18 | -6.91 |
| 2024-11-15 | -7.37 |
| 2024-11-14 | -7.36 |
| 2024-11-13 | -6.87 |
| 2024-11-12 | -7.18 |
| 2024-11-11 | -6.49 |
| 2024-11-08 | -6.27 |
| 2024-11-07 | -5.67 |
| 2024-11-06 | -5.37 |
| 2024-11-05 | -5.43 |
| 2024-11-04 | -5.47 |
| 2024-11-01 | -5.66 |
| 2024-10-31 | -5.80 |
| 2024-10-30 | -5.77 |
| 2024-10-29 | -5.85 |
| 2024-10-28 | -5.95 |
| 2024-10-25 | -6.00 |
| 2024-10-24 | -6.04 |
| 2024-10-23 | -6.17 |
| 2024-10-22 | -6.27 |
| 2024-10-21 | -6.14 |
| 2024-10-18 | -6.21 |
| 2024-10-17 | -6.43 |
| 2024-10-16 | -6.15 |
| 2024-10-15 | -6.00 |
| 2024-10-14 | -6.06 |
| 2024-10-11 | -6.09 |
| 2024-10-10 | -6.07 |
| 2024-10-09 | -5.68 |
| 2024-10-08 | -5.79 |
| 2024-10-07 | -5.69 |
| 2024-10-04 | -5.55 |
| 2024-10-03 | -6.06 |
| 2024-10-02 | -6.16 |
| 2024-10-01 | -6.05 |